Interactions between cannabinoid and opioid receptors in a mouse model of diabetic neuropathy

Author(s)

Toniolo, Elaine F. ; Gupta, Achla ; Franciosi, Adriano C. ; Gomes, Ivone ; Devi, Lakshmi A. ; Dale, Camila S.

• Document type: Journal article
• Source: Pain; v. 163, n. 7, p. 10-pg., 2022-07-01.

Abstract

Diabetic neuropathy, often associated with diabetes mellitus, is a painful condition with no known effective treatment except glycemic control. Studies with neuropathic pain models report alterations in cannabinoid and opioid receptor expression levels; receptors whose activation induces analgesia. We examined whether interactions between CB1R and opioid receptors could be targeted for the treatment of diabetic neuropathy. For this, we generated antibodies that selectively recognize native CB1R-MOR and CB1R-DOR heteromers using a subtractive immunization strategy. We assessed the levels of CB1R, MOR, DOR, and interacting complexes using a model of streptozotocin-induced diabetic neuropathy and detected increased levels of CB1R, MOR, DOR, and CB1R-MOR complexes compared with those in controls. An examination of G-protein signaling revealed that activity induced by the MOR, but not the DOR agonist, was potentiated by low nanomolar doses of CB1R ligands, including antagonists, suggesting an allosteric modulation of MOR signaling by CB1R ligands within CB1R-MOR complexes. Because the peptide endocannabinoid, hemopressin, caused a significant potentiation of MOR activity, we examined its effect on mechanical allodynia and found that it blocked allodynia in wild-type mice and mice with diabetic neuropathy lacking DOR (but have CB1R-MOR complexes). However, hemopressin does not alter the levels of CB1R-MOR complexes in diabetic mice lacking DOR but increases the levels of CB1R-DOR complexes in diabetic mice lacking MOR. Together, these results suggest the involvement of CB1R-MOR and CB1R-DOR complexes in diabetic neuropathy and that hemopressin could be developed as a potential therapeutic for the treatment of this painful condition. (AU)

• FAPESP's process: 12/50176-5 - Effect of hemopressin - an inverse agonist of cannabinoid receptors type 1 - in diabetes mellitus-induced neuropathy in mice
• Grantee: Camila Squarzoni Dale
• Support Opportunities: Regular Research Grants